+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Oncology Drugs Market - Global Forecast 2026-2032- Product Image
Generic Oncology Drugs Market - Global Forecast 2026-2032- Product Image
New

Generic Oncology Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6017361
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global generic oncology drugs market is experiencing significant evolution, shaped by scientific advances, regulatory changes, and shifting care pathways. Senior decision-makers must navigate increasing complexity across drug development, supply chains, and commercialization models to secure sustainable patient access and competitive advantage.

Market Snapshot: Generic Oncology Drugs Market Overview

The Generic Oncology Drugs Market grew from USD 41.51 billion in 2025 to USD 44.65 billion in 2026. It is expected to continue growing at a CAGR of 7.13%, reaching USD 67.25 billion by 2032. Leadership teams must closely monitor evolving therapeutic standards and align commercial and operational strategies for continued market participation.

Scope & Segmentation

  • Drug Modalities: Includes biologics, small molecules, cell therapies, targeted agents, and cytotoxic compounds.
  • Indication Diversity: Addresses a range of cancer types such as breast, colorectal, leukemia, lung, lymphoma, and prostate, each presenting unique clinical and commercialization pathways.
  • Distribution Channels: Encompasses hospital, retail, and online pharmacies, each supporting distinct access and adherence models.
  • Administration Routes: Covers intravenous, oral, and subcutaneous forms, spanning site-of-care preferences and device compatibility.
  • Therapy Lines: Analysis across first-line, second-line, and third-line-plus regimens, focusing on varying evidence requirements and clinical value.
  • Mechanism Taxonomy: Chemotherapy, immunotherapy (including CAR-T and checkpoint inhibitors), and targeted therapies (notably monoclonal antibodies and kinase inhibitors).
  • Formulation Impacts: Examines liquid, tablet, and lyophilized powder formulations in relation to stability, dosing, and supply chain parameters.
  • Regional Perspectives: Evaluation across the Americas, EMEA, and Asia-Pacific, emphasizing regulatory diversity, reimbursement environments, and localized commercial strategies.

Key Takeaways for Senior Decision-Makers

  • Scientific innovation is driving the diversification of oncology drug classes, requiring agility in research, regulatory adaptation, and health technology assessment alignment.
  • Supply chain management is increasingly complex, demanding robust risk mitigation, nearshoring strategies, and enhanced digital tracking across biologic modalities and advanced therapies.
  • Evidence generation now integrates both clinical trial and real-world data, supporting differentiated value propositions and favorable reimbursement outcomes in fragmented payer markets.
  • Strategic alliances—spanning academic, biotech, and service partners—are central to accessing early-stage innovation, managing risk, and accelerating time-to-market for new therapies.
  • Workforce development is essential, with emphasis on cross-functional expertise in regulatory, logistics, and value demonstration amidst evolving therapeutic standards.

Tariff Impact: U.S. Policy Shifts and Commercial Implications

U.S. tariff changes in 2025 have triggered reassessments of sourcing, procurement, and contracting for oncology medicines. Manufacturers are qualifying new suppliers, scaling onshore capacity, and optimizing packaging flows to manage cost volatility and ensure compliance. Distributors and healthcare providers are adapting procurement frameworks to maintain uninterrupted supply, prompting advanced dialogue with payers and innovative contracting structures. Enhanced customs expertise and technology-enabled documentation now underpin critical cross-border logistics.

Methodology & Data Sources

This report leverages a multi-source research approach, including structured interviews with subject-matter experts, systematic review of regulatory documents, and synthesis from peer-reviewed literature and public clinical trial datasets. Scenario-based validation ensures strategic insights are rigorously tested for reliability.

Why This Report Matters

  • Enables informed planning around scientific innovation, supply chain resilience, and evolving payer expectations within the generic oncology market.
  • Supports risk assessment and investment decisions by presenting in-depth regulatory, regional, and operational segmentation insights.
  • Equips leadership with actionable strategies for evidence generation, manufacturing diversification, and commercial model adaptation.

Conclusion

Integrated strategies that align scientific progress, operational resilience, and payer-focused evidence will be critical for ensuring patient access and commercial success in oncology therapeutics. Responsive, collaborative approaches are essential as this market continues to advance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Generic Oncology Drugs Market, by Drug Type
8.1. Biologics
8.2. Small Molecule
9. Generic Oncology Drugs Market, by Indication
9.1. Breast Cancer
9.2. Colorectal Cancer
9.3. Leukemia
9.4. Lung Cancer
9.5. Lymphoma
9.6. Prostate Cancer
10. Generic Oncology Drugs Market, by Distribution Channel
10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies
11. Generic Oncology Drugs Market, by Route Of Administration
11.1. Intravenous
11.2. Oral
11.3. Subcutaneous
12. Generic Oncology Drugs Market, by Therapy Line
12.1. First-Line
12.2. Second-Line
12.3. Third-Line Plus
13. Generic Oncology Drugs Market, by Mechanism Of Action
13.1. Chemotherapy
13.2. Immunotherapy
13.2.1. CAR-T Therapy
13.2.2. Checkpoint Inhibitors
13.3. Targeted Therapy
13.3.1. Monoclonal Antibodies
13.3.2. Tyrosine Kinase Inhibitors
14. Generic Oncology Drugs Market, by Formulation
14.1. Liquid
14.2. Lyophilized Powder
14.3. Tablet
15. Generic Oncology Drugs Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Generic Oncology Drugs Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Generic Oncology Drugs Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Generic Oncology Drugs Market
19. China Generic Oncology Drugs Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Accord Healthcare Ltd.
20.6. Amneal Pharmaceuticals Inc.
20.7. Aspen Pharmacare Holdings Ltd.
20.8. Aurobindo Pharma Ltd.
20.9. Biocon Limited
20.10. Celltrion Healthcare Co., Ltd.
20.11. Cipla Inc.
20.12. Dr. Reddy's Laboratories Ltd.
20.13. Fresenius Kabi AG
20.14. Gedeon Richter Plc.
20.15. Glenmark Pharmaceuticals Ltd.
20.16. Hikma Pharmaceuticals Plc
20.17. Intas Pharmaceuticals Ltd.
20.18. KRKA d.d., Novo mesto
20.19. Lupin Pharmaceuticals Inc.
20.20. MSN Laboratories
20.21. Sandoz Group AG
20.22. Sawai Pharmaceutical Co., Ltd
20.23. Shanghai Fosun Pharmaceutical Group Co., Ltd.
20.24. STADA Arzneimittel AG
20.25. Sun Pharmaceutical Industries Ltd.
20.26. Teva Pharmaceutical Industries Ltd.
20.27. Torrent Pharmaceuticals Ltd.
20.28. Viatris Inc.
20.29. Zydus Cadila Healthcare Ltd.
List of Figures
FIGURE 1. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 139. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 153. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 155. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 156. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 159. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 160. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 161. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 162. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 176. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 180. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 181. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 182. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 183. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 184. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 186. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 187. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 190. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 191. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 192. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 193. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 204. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 206. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 207. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 210. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 211. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 212. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 213. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 214. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 216. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 220. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 221. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 222. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 223. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 224. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 225. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 226. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 227. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 230. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 231. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 232. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 233. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 245. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 247. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 248. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 249. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 251. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 252. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 253. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 254. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Generic Oncology Drugs market report include:
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Aurobindo Pharma Ltd.
  • Biocon Limited
  • Celltrion Healthcare Co., Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Intas Pharmaceuticals Ltd.
  • KRKA d.d., Novo mesto
  • Lupin Pharmaceuticals Inc.
  • MSN Laboratories
  • Sandoz Group AG
  • Sawai Pharmaceutical Co., Ltd
  • Shanghai Fosun Pharmaceutical Group Co., Ltd.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Cadila Healthcare Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 44.65 Billion
Forecasted Market Value ( USD ) by 2032 $ 67.25 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Generic Oncology Drugs Market Report 2025 - Product Image

Generic Oncology Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033 - Product Image

Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033

  • Report
  • 139 Pages
  • Global
From
Generic Oncology Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Generic Oncology Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Oncology Drugs Market - Global Forecast 2026-2032 - Product Image

Oncology Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Cancer Supportive Care Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Supportive Care Drugs Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From

About the Generic Oncology Drug Market

The Generic Oncology Drug market is a subset of the larger Generic Drug market. Generic Drugs are copies of brand-name drugs that have the same active ingredients, dosage form, strength, route of administration, safety, efficacy, and intended use as the original drug. Generic Oncology Drugs are used to treat cancer and are typically much less expensive than their brand-name counterparts. Generic Oncology Drugs are typically available in oral, injectable, and topical forms. Generic Oncology Drugs are subject to the same regulatory standards as brand-name drugs, and must meet the same safety and efficacy requirements. Generic Oncology Drugs are typically available in the same dosage forms and strengths as their brand-name counterparts. Some companies in the Generic Oncology Drug market include Mylan, Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.